分泌型IgA联合常规抗感染药物治疗对小儿上呼吸道感染炎症反应、免疫应答的影响

摘要

目的:探讨分泌型Ig A联合常规抗感染药物治疗对小儿上呼吸道感染炎症反应、免疫应答的影响.方法:选取2016年2月～2017年2月在本院就诊的上呼吸道感染小儿130例,经随机数表法将其分为对照组、分泌型Ig A组各65例.对照组接受常规抗感染药物治疗,分泌型Ig A组接受分泌型Ig A联合常规抗感染药物治疗,持续1周.对比两组患者治疗前后血清中常规炎症因子、脂肪炎症因子、免疫球蛋白含量的差异.结果:治疗前,两组血清中常规炎症因子、脂肪炎症因子、免疫球蛋白含量的差异无统计学意义.治疗1周后,分泌型IgA组血清中常规炎症因子CRP、IL-1、IL-8的含量低于对照组;血清中脂肪炎症因子SAA、Chemerin的含量低于对照组,Leptin的含量高于对照组;免疫球蛋白IgA、IgG、IgM的含量高于对照组.结论:小儿上呼吸道感染接受分泌型IgA联合常规抗感染药物治疗,可有效抑制全身炎症反应并增强体液免疫应答.%Objective:To investigate the effect of secretory IgA combined with conventional anti-infectious drugs on in-flammatory response and immune response in children with upper respiratory tract infection .Methods:A total of 130 children with upper respiratory tract infection who were treated in the hospital between February 2016 and February 2017 were divided into control group and secretory IgA group by random number table method ,each group with 65 cases .Control group received routine anti-infectious drug treatment ,and secretory IgA group received the secretory IgA combined with conventional anti-in-fectious drug treatment ,which lasted for 1 week .The differences in serum levels of routine inflammatory factors ,fat inflam-matory factors and immunoglobulin were compared between the two groups before and after treatment .Results:There was no statistically significant difference in serum levels of normal inflammatory factors ,fat inflammatory factors and immunoglobulin between the two groups before treatment .After 1 week of treatment ,serum conventional inflammatory factors CRP ,IL-1 and IL-8 levels of secretory IgA group were lower than those of control group ;serum fat inflammatory factors SAA and Chemerin levels were lower than those of control group whereas Leptin level was higher than that of control group ;serum immunoglobu-lin IgA ,IgG and IgM contents were higher than those of control group .Conclusions:The secretory IgA combined with conven-tional anti-infectious drugs can effectively inhibit the systemic inflammatory response and enhance the humoral immune re-sponse in children with upper respiratory tract infection .